Purpose: To demonstrate a new MR imaging approach that unambiguously identifies and quantitates contrast agents based on intrinsic agent properties such as r 1 , r 2 , r Ã 2 , and magnetic susceptibility. The approach is referred to as magnetic barcode imaging (MBI). Methods: Targeted and bioresponsive contrast agents were imaged in agarose phantoms to generate T 1 , T 2 , T Ã 2 , and quantitative susceptibility maps. The parameter maps were processed by a machine learning algorithm that is trained to recognize the contrast agents based on these parameters. The output is a quantitative map of contrast agent concentration, identity, and functional state. Results: MBI allowed the quantitative interpretation of intensities, removed confounding backgrounds, enabled contrast agent multiplexing, and unambiguously detected the activation and binding states of bioresponsive and targeted contrast agents. Conclusion: MBI has the potential to overcome significant limitations in the interpretation, quantitation, and multiplexing of contrast enhancement by MR imaging probes. Magn Reson Med 77:970-978,
INTRODUCTION
Magnetic resonance imaging interrogates deep tissues at high resolution without the use of ionizing radiation. This unique combination of attributes is ideal for molecular imaging, which uses specialized contrast agents to visualize cellular and biomolecular processes in whole organisms (1) . Two types of contrast agents are used in molecular MRI: targeted agents with affinity for molecular markers (2) (3) (4) and bioresponsive agents that activate in response to biological cues (5-7). Current imaging methods that rely on T 1 or T 2 weighting limit the application of these agents in several significant ways. First, agent contrast enhancements often appear ambiguous against complex backgrounds; second, quantitative information is lacking because of nonlinear signals; third, enhancements from unbound targeted agents lead to false detections; fourth, bioresponsive agent activation is easily confused with concentration variations because both appear as an increase in signal (8) ; and lastly, grayscale outputs make simultaneous probing with multiple agents extremely challenging (9, 10) .
A major research goal is to obtain molecular MRI that is unambiguous, multiplexed, and quantitative. These properties have been attained in the past by exploiting unique resonances provided by contrast agent platforms such as micromachined magnets (10) , chemical exchange saturation transfer agents (11) , and hyperpolarized xenon gas vesicles (12) . However, gadolinium complexes (13) and iron oxide particles (14) continue to serve as the mainstay platforms for molecular MRI because of their ease of chemical modification, sensitivity, and long imaging time window.
A new imaging technique that overcomes the current shortcomings of gadolinium and iron oxide imaging would quickly affect a range of applications by taking advantage of the facile functionalization, high stability, and biological tolerance of established contrast agents. Progress has been made in the quantitative and specific imaging of these agents using ratiometric methods that measure two relaxation times (15) (16) (17) . Beyond contrast agent imaging, a more generalized approach measuring more parameters has been long applied to the machine learning detection of tissue pathologies (18) (19) (20) (21) (22) . Despite this history, multiparameter imaging has not penetrated in a significant way into the contrast agent community to address the shortcomings of molecular MR imaging (23) . Contrast agents present unique challenges distinct from those applicable to tissues, because no data set is readily available for machine learning, the MR parameters change as a function of agent concentration and tissue background, and the design of pulse sequence combinations cannot be based on experiences from tissues.
Here, we have developed and demonstrated a framework that combines multiparameter MR acquisitions with supervised machine learning as applied to molecular MR imaging, to distinguish contrast agents by their susceptibility and relaxometric signatures (Fig. 1) . The approach, called magnetic barcode imaging (MBI), specifically highlights theoretically any contrast agent in an image. By assigning different "colors" to individual signatures associated with contrast agents and their functional states, MBI can (1) display contrast enhancement with zero background, (2) distinguish between bound and unbound states of targeted agents, (3) unambiguously detect the activation of bioresponsive agents, and (4) support the simultaneous imaging of multiple types of contrast agents in a single acquisition. Importantly, by performing regression learning, quantitation can be realized by MBI.
The MBI framework can be implemented in many ways, depending on the pulse sequences and the machine learning strategy used. Optimized algorithms of acquisition and processing in different in vivo settings, as well as the accumulation of large training data sets that capture contrast agents in complex in vivo environments, would require a research effort across many research groups. Such an effort requires proof of concept. To this end, we prove that the detection of MR contrast agent concentration, type, chemical state, and localization is possible by MBI in vitro using an implementation that barcodes by T 1 , T 2 , T Ã 2 , and susceptibility maps. The capabilities of MBI were demonstrated on both gadolinium and iron oxide contrast agents across a range of applications.
METHODS

Contrast Agents
Gd(III)-daa was synthesized using a previously described protocol (24) . The version of Gd(III)-daa used has a 5-carbon linker.
Synthesis of Gd(III)-biotin employed the synthetic strategy described in (25) to achieve 3-(2,4,6)-Tris (1-2(hydroxyl-3-(1H-1,2,3-triazol-1-yl(propyl)-3,7,10-tris (carboxymethyl)-1,4,7,10-tetraazacyclododecylgadolinium (III)phenoxy)-propan-1-amine (C3-amine). C3-amine (1.6 mg, 0.0008 mmol) was suspended in 200 mL, pH 9.4 bicarbonate buffer under inert atmosphere. To the stirring solution was added biotin N-hydroxysuccinimide ester (26) (1.2 mg, 0.0035 mmol) dissolved in 100 mL of dimethyl sulfoxide. After 24 h, the solvent was removed by lyophilization and the product purified by reversephase high-performance liquid chromatography using a C18 column, held at 5% for 5 min, and eluting with a gradient of 5 to 20% acetonitrile in pH 10.38 buffered water over 21 min, t r ¼ 11.8 min. This gave 1.1 mg of pure product as a white solid (55% yield). (MS (MALDI-TOF 
.) Superparamagnetic iron oxide (SPIO) was synthesized using a published method (27) . The SPIO used was surface-functionalized with diethylene glycol. Feridex was purchased from Bayer HealthCare (Wayne, New Jersey). MPIO was purchased from Bangs Laboratories (Cat. No. ME03F, Fishers, Indiana). Concentrations of agents were measured using ICP-MS. Iron oxide particle concentrations reported are Fe concentrations. Gd(III)-biotin concentrations reported are molecular concentrations. MPIO concentrations reported in mg/mL include polymeric weight and were based on the supplier label.
Training Agarose Phantoms
All agarose phantoms used for radial basis function neural network (RBFNN) training were prepared in a similar fashion, consisting of contrast agent-doped 1% low melting point (lowMP) agarose (Life Technologies, Carlsbad, California), embedded within blank 1% regular agarose. Two percent agarose in milliQ water and a buffer were mixed in equal parts to produce 1% agarose. The buffer used was 10 mM HEPES for Gd(III)-daa, 10 mM PBS for Gd(III)-biotin, and milliQ water for SPIO, Feridex, and MPIO in the multiplexing experiment. MPIO training for the zero-background experiment was performed using 10% serum-supplemented minimum essential media mixed with 2% agarose in equal parts (media-agarose). All samples were prepared in 15-mL conical tubes. Four milliliters of 1% agarose was gelled at room temperature around a 5-mm OD nuclear magnetic resonance (NMR) tube. The tube was later removed to create a cylindrical bore of approximately 1 cm in depth. The bore was filled with 220 mL of 1% lowMP agarose doped with the appropriate concentration of contrast agent. Concentrations are specified in the methods of each individual experiment. After filling, the tube was cooled to 4 C for 5 min to solidify the doped lowMP agarose. To the same tube, 2 mL of 1% agarose was added and solidified for 5 min at 4 C to completely enclose the doped lowMP agarose. Approximately 5 mL of the same buffer used to prepare the agarose was diluted to 10 mL with milliQ water and added on top of the agarose plug to completely fill the tube. Diffusion in agarose occurred for small molecule contrast agents. Therefore, imaging was performed immediately after preparation of the phantom.
Magnetic Barcode Acquisition
Imaging was performed at 25 C on a Bruker Pharmscan 7 Tesla (T) imaging spectrometer equipped with shielded gradient coils (Bruker BioSpin, Billerica, Massachusetts). A 300 MHz 1 H 89-mm/23-mm quadrature transceiver volume coil was used. The Bruker MapShim method was used for shimming. T 1 measurements were performed using a rapid acquisition with refocused echoes (RARE) pulse sequence. T 2 measurements were performed using a multispin echo (MSE) pulse sequence. T Ã 2 measurements were performed using a multigradient echo (MGE) pulse sequence. Field map measurements used for susceptibility mapping were performed using the Bruker FieldMap macro based on a double gradient echo pulse sequence. Unless otherwise specified, the geometries for T 1 , T 2 , and T Barcode Processing and Machine Learning T 1 and T 2 maps were generated using custom programs written in MATLAB (version R2010b, MathWorks, Natick, Massachusetts). For T 1 , each voxel in a TR series of images was fitted to the equation
, in which S is the signal, and M is the equilibrium magnetization. S and TR were known; M and T 1 were fitted. For T 2 , each voxel in a TE series of images was fitted to the equation S ¼ MÁexp(ÀTE/T 2 )þC, in which C is an arbitrary constant that is fitted. T Ã 2 was fitted in the same way as T 2 . Susceptibility maps were generated based on field maps using the quantitative susceptibility mapping (QSM) algorithm described by de Rochefort et al (28) . Field map voxels with signal-to-noise ratio < 6 were set to zero. Regions of interest (ROIs) were defined by the nonzero regions in the field map. Manual corrections were performed to include air bubbles within the sample into the regions of interest. The top and bottom five rows of the field maps were removed to minimize interference from field inhomogeneity during QSM processing. Tuning of the conjugate gradient loop stop criterion and the edge regularization parameter was performed manually; values that result in stable solutions that do not vary significantly with the parameters were selected. These parameters were kept the same across training and testing for each experiment. Procedures for automatic parameter selection are available (28) but were not implemented. RBFNN training and image processing were performed in MATLAB using the neural network toolbox. Two hundred voxels from each training agarose phantom were randomly selected and aggregated to form the training set for each contrast agent or agent functional state. For Gd(III)-daa and Gd(III)-biotin, 200 additional training data points were generated by interpolation to provide coverage for partial Gd(III)-daa activation and partial Gd(III)-biotin binding. Each training set was normalized by its own mean and standard deviation. An empirical relationship between susceptibility, as obtained by QSM, and concentration, as measured by ICP-MS, was then found by linear fitting. The empirical equation was used to calculate the answer vector containing concentrations for multivariate regression training. The number of nodes in the RBFNN was restricted to less than 500. A spread of 0.1-0.3 and a mean error goal of <10% were used. These parameters were not optimized, and the accuracy of RBFNN regression can be further improved by techniques such as cross-validation and ROC curve analysis.
Relaxivity and Susceptibility Measurement
The r 1 , r 2 , and r . The x M of each agent was obtained in a fashion similar to how relaxivities were measured, except that x M was found as the slope of x linearly fitted against concentration in units of ppm/M. x M was calibrated against the theoretical Gd(III) value of 326 ppm/M (29) using a calibration factor obtained by comparing the Gd(III)-daa data to the theoretical value.
Zero-Background Imaging
The test phantom was prepared in a 4 mL 15 Â 45 mm glass vial. A total of 2 mL of 1% media-agarose warmed at 70 C was added to the vial. As the agarose gelled, 10 mL each of 8 mg/mL MPIO and 2.3 mM FeCl 3 in 1% media-lowMP agarose warmed at 60 C was carefully infused in two separate spots. Next, 10 mL of dodecanol was infused in a third location. The 1% media-lowMP agarose was colored by 2.5% v/v trypan blue for visibility. The sample was solidified for 5 min at 4 C before 2 mL more of 1% media-agarose was added and cooled at 4 C for 5 min. Media diluted 2X by milliQ water was added at the end to completely fill the vial. RBFNN training was performed using 0, 2, 4, 6, 8, and 10 mg/mL MPIO. Detailed imaging parameters are as follows: for T 1 
Multiplexed Imaging
The test phantom was prepared in a 15-mL conical tube. A total of 12 mL of 1% agarose was gelled at RT around five 16-G needles that were later removed to create cylindrical bores in the agarose. One-percent lowMP agarose warmed at 60 C and doped with various concentrations of SPIO, Feridex, and MPIO were used to fill the cylindrical bores. Contrast agent concentrations are indicated in the relevant figure. The volume used for each bore was 25 mL. The sample was cooled at 4 C for 5 min to solidify the lowMP agarose. A total of 2 mL more of 1% agarose was added and solidified at 4 C for 5 min to completely encapsulate the embedded contrast agent. The remainder of the tube was filled with milliQ water. RBFNN training was performed using 240 and 320 mM Fe SPIO, 60 and 80 mM Fe Feridex, 60 and 80 mM Fe MPIO, 120/30 and 160/ 40 mM Fe SPIO/Feridex mixture, and 120/30 and 160/ 40 mM Fe SPIO/MPIO mixture. Additionally, blank 1% agarose was included in the training set to define the zero point for regression training. Detailed imaging parameters are as follows: For T 1 
RESULTS
MBI uniquely identifies contrast agents and their functional states by signatures that are encoded in the magnetic properties and the molecular dynamics of each agent. To capture these signatures, an MBI implementation consists of a selection of acquisition pulse sequences, a preprocessing protocol, and a machine learning strategy (Fig. 2) . Together, these components determine the barcode space dimensionality, the accuracy and precision of the measured parameters, and the classification and quantitation accuracy. The implementation reported here uses multigradient echo and Carr-Purcell-MeiboomGill multispin echo sequences to measure T 1 , T 2 , T Ã 2 , and phase-based susceptibility (x) in a voxel-by-voxel manner (30) . This combination of pulse sequences captures the corresponding agent relaxivities and molar susceptibility (r 1 , r 2 , r Ã 2 , x M ). For preprocessing, relaxation times were estimated by least-squares fitting to known signal equations, and susceptibility was obtained using a morphology-enabled dipole inversion method devised by de Rochefort et al (28) Machine learning was performed by a radial basis function neural network (31) (RBFNN), trained on contrast agent phantoms prepared at a range of concentrations (Fig. 2a) . RBFNN was chosen because it is amenable to training without negative examples, it outputs posterior Bayesian probabilities, and it handles regression problems well. Depending on the training set used, the RBFNN can learn to highlight a single contrast agent from the background, or use different colors to represent different agents or different functional states of a single agent. The different RBFNN configurations used to achieve the different outputs are described in the results for each experiment.
Zero-Background Imaging
Micron-sized superparamagnetic iron oxide particles (MPIOs) are used customarily in T 2 -weighted MRI. These agents generate negative contrast that are often confounded by hypo-intensive features such as air, hemorrhage, iron-rich tissues, or calcification (32) . In theory, a RBFNN trained to recognize MPIOs would differentiate the contrast agent from the confounding features. To test this hypothesis, MBI was performed on an agarose phantom embedding 8 mg/mL MPIO, fat-mimicking dodecanol, and 2.3 mM FeCl 3 simulating a hemorrhage. Training of the RBFNN was performed using 0-10 mg/mL MPIO.
MBI successfully distinguished MPIO from dodecanol and Fe 3þ , whereas T 2 -weighted imaging showed all three as undifferentiated hypo-intensities (Fig. 2c) . On MBI, the MPIO contrast is displayed as a quantitative intensity without background. MBI recapitulates the major advantages of quantitation and zero background in nuclear imaging-considered the gold standard in clinical molecular imaging-without the radiation risk and at a higher resolution.
Detection of Bioresponsive Agent Activation
To test MBI on a bioresponsive agent, Gd(III)-diaminoacetate (Gd(III)-daa) was used as a model system. Gd(III)-daa is a Zn 2þ sensor that allows water coordination to Gd(III) upon Zn 2þ binding (24, 33) . The binding event leads to an increase in the r 1 and r 2 to the agent's barcode (Fig. 3a) . r Ã 2 is degenerate with r 2 in Gd(III)-daa and not used. The RBFNN for this system was constructed with two output nodes to represent the concentrations of Gd(III)-daa in its off and activated state, respectively. The training performed on the agent was with and without Zn 2þ at a range of concentrations. Once the training was complete, testing was performed using concentrations not seen during training to demonstrate external validity.
The standard method for imaging bioresponsive Gd(III) agents is T 1 -weighted imaging. However, a major limitation of this method is evidenced by its inability to distinguish an activation event from an increase in agent concentration, as Gd(III)-daa produces residual contrast in its "off" (absence of Zn 2þ ) state (Fig. 3a) . In contrast, MBI unambiguously differentiates between the functional states of Gd(III)-daa regardless of concentration. Concentration is quantitatively displayed, allowing for the detection of partial activation when less than one equivalent Zn 2þ is present. Therefore, MBI removes the obstacle of ambiguity in the imaging of Gd(III) bioresponsive agents.
Detection of Targeted Agent Binding
MBI can detect the binding of a targeted agent to the selected molecular target, analogous to the way differentiation is achieved with bioresponsive agent activation. To test this capability, an avidin-targeted agent (Gd(III)-biotin) was used. Using the same barcode design as Gd(III)-daa, Gd(III)-biotin phantoms with and without avidin across a range of concentrations were imaged for training. Upon Gd(III)-biotin binding to avidin, the molecular rotation slowed, decreasing r 1 and increasing r 2 (Fig. 3b) . As before, testing was performed using concentrations that differ from those in the training set.
The goal of a targeted agent is to delineate the presence of a molecular marker from the background tissues. However, nonspecific retention can compromise the interpretation of the results. Under standard T 1 -weighted imaging, the binding status of the agent is unidentifiable (Fig. 3b) . In comparison, MBI quantitatively displays the binding status of the contrast agent as a change in color by differentiating between the barcodes of the bound and unbound states. Furthermore, MBI distinguishes between partial binding and saturation depending on whether Gd(III)-biotin or avidin is in excess. When human serum albumin instead of avidin was mixed with Gd(III)-biotin, MBI accurately identified the agent as unbound. The ability to switch color upon protein binding of a small molecule targeted contrast agent is a unique capability of MBI that has not been demonstrated with any other imaging modality.
Multiplexing of Iron Oxide Particles
Multiplexing in molecular imaging refers to the simultaneous visualization of multiple imaging agents (34) . This capability is important because there is increasing realization that no single biomarker is likely to provide sufficient characterization of a disease process (35) . Magnetic particles have the potential to serve as a platform for MR multiplexing because their magnetic and dynamic properties change with size, composition, and geometry (36) . However, this potential has not been fully realized.
Using MBI, multiplexing was tested with superparamagnetic iron oxide nanoparticles (SPIOs), Feridex, and MPIOs. RBFNN training was performed on the individual particles and mixtures of particles. All three particles used were Fe 3 O 4 in material, but of different sizes and configurations, producing distinct barcodes (Fig. 4) . By T 2 -weighted MRI, the three particles embedded in agarose produce hypo-intensities that are indistinguishable from each other. When the same specimen is imaged by MBI, each particle is displayed as a different color on a quantitative scale, even in mixtures. This result supports the notion that magnetic particles can be multiplexed via the tuning of their size and shape.
DISCUSSION
We have demonstrated a proof of concept of the magnetic barcoding framework across a range of targeted, bioresponsive, gadolinium, and iron oxide contrast agents. By abandoning the treatment of T 1 and T 2 as a dichotomy, barcoding opens up several opportunities for MR contrast agent design. For example, an emerging strategy to enable quantitation and specific detection in molecular MRI is to synthesize multimodal probes (8, 37) . MBI helps to achieve the same goal while allowing the contrast agent design to remain simple. Another burdensome task in traditional contrast agent development is its optimization for different field strengths. MBI alleviates this need as evidenced by its successful detection of Gd(III)-biotin binding at 7 T, even though the agent was optimized for 1.5 T and lost its property of binding-induced r 1 enhancement at the higher field strength. Further opportunities lie in the parametertuning of contrast agents. MBI turns the old design rule of maximizing or minimizing r 1 /r 2 ratio upside down as sensitivity and specificity are maximized with a balanced ratio in a multiparameter framework. Similarly, engineering the traditionally ignored r Ã 2 becomes valuable in MBI because it adds a dimension to barcode space, as shown by MPIO. These properties imply that the performance of MBI is further optimized when matched to specifically designed contrast agents.
To translate the proof-of-concept results described here in vivo, further iterative development of the technique will need to focus on two areas. First, acceleration is needed because motion and time-varying contrast agent concentrations in vivo necessitate scan times on the order of a minute. In comparison, an acquisition by the current implementation takes approximately 30 min. Incorporation of compressed sensing (38) , steady-state free precession (39), or parallel imaging (40) into future iterations can shorten scan times by a factor of between 10-100 fold.
Second, the additional complexities associated with tissue background in vivo need to be addressed. Fundamentally, T 1 , T 2 , T Ã 2 , and x are determined by both the contrast agent and the tissue background. To account for the greatly increased number of combinations in vivo compared with in phantoms, the training set used for machine learning would need to be expanded. One way to perform the expansion is to computationally add the relaxation rates and susceptibilities of blank tissues to those of the contrast agents; alternatively, training can be performed by imaging a collection of contrast-infused tissues ex vivo. The latter strategy would be preferred if the agent barcode changes substantially in the tissue microenvironment. The likelihood of such a change depends on the barcode design, the contrast agent used, the compartmentalization of the contrast agent, and tissue properties such as diffusion. Therefore, the extensiveness and the method of MBI training will vary with the imaging . xM is in ppm/M. problem being addressed. Continual advancement of MBI in the two areas of speed and training set development is expected to enable its use in vivo.
Other important areas of future MBI development will include strategies for handling highly heterogeneous backgrounds, new barcode designs, and applications of various machine learning algorithms. Although multiparametric MR approaches have been explored extensively for tissue imaging, the unique challenges and opportunities of the approach in molecular MRI warrant a separate effort. For example, variations resulting from agent concentration and the numerous possible agent-tissue combinations are not a concern in tissue imaging. This property adds to the complexity of MBI machine learning when applied to a highly heterogeneous background. In addition to obtaining large training sets as already discussed, a strategy for addressing this complexity would be to exploit pulse sequences that are more sensitive to magnetic materials than tissues, such as QSM or off-resonance imaging (41, 42) . This strategy circumvents the more cumbersome method of acquiring prescans for background removal, and illustrates the unique opportunities to innovate in multiparameter contrast agent imaging that is distinct from the challenges of tissue imaging.
In relation to other approaches that similarly aim to address the shortcomings of T 1 -and T 2 -weighted contrast agent imaging, we view MBI as a complementary rather than a competing approach. At its core, MBI is a framework for integrating multidimensional image data into an output with emergent attributes that are highly desirable in a molecular imaging study. The use of machine learning circumvents the challenge of having to reinvent image analysis every time a new parameter is added to the acquisition. Pulse sequences such as T 1r mapping (43) , intermolecular multiple quantum coherences (44), ultrashort echo time relaxometry (45) , and dispersion imaging (46) can be employed under the MBI framework to further improve multiplexing degree, sensitivity, and accuracy. Similarly, signal intensities rather than fitted parameters can be explored as barcode components; this type of implementation has the advantage of improved accuracy when there are heterogeneous tissue types within a voxel. Furthermore, a wide array of machine learning (47) (48) (49) and susceptibility mapping algorithms (50) (51) (52) exist that can be applied within the MBI framework to reduce processing artifacts and improve quantitation and classification accuracy. As an example, in the current implementation, the quantitative maps produced are multiplicative products of concentration and Bayesian probability. That is, voxels with low classification confidence display underestimated concentrations in exchange for fewer false positives. In our data set, the largest underestimation found is with the SPIOs at 15%, whereas the false positive rate as determined by the percentage of voxels with grossly overestimated concentrations is <10%. This type of trade-off can be modified by the processing algorithm design.
CONCLUSIONS
MBI uniquely enables the multiplexing, quantitation, and specific detection of MRI contrast agents, conferring on them the advantages that were once exclusive to optical and nuclear imaging. The framework, when implemented fully, will remove a significant barrier toward the routine use of molecular MRI, and opens new possibilities for contrast agent design, biomarker quantitation, and multimarker detection of pathologies.
